Carregant...
PD-1/PD-L1免疫检查点抑制剂在肺癌中的研究进展
In recent years, research on immunotherapy has made great progress. Currently, immunotherapy has made significant breakthrough, especially programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors (e.g, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab and Avelumab, etc.) have...
Guardat en:
| Publicat a: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
中国肺癌杂志编辑部
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6580087/ https://ncbi.nlm.nih.gov/pubmed/31196371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2019.06.07 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|